Add a listing
    Add a listing

    EnClear Therapies

      Device based filtering and modifying of cerebrospinal fluid to treat neurodegenerative disease.

    General
    • Headquarters

      Newburyport, Massachusetts, United States

    • Founders & Team

      Anthony DePasqua, Kevin Eggan

    • Year Founded

      2018

    • Number of employees

      10

    • Company type

      Private company

    • Funding stage

      Series A

    • Total funding ($M)

      12.0

    • Investors

      Thiel Capital, Amgen Ventures, Presight Capital

    Technical Details
    • Disease indication

      ALS, dementia, Progressive supra nuclear palsy

    • Product modality

      medical device

    About

    EnClear Therapies was conceived with the sole purpose of developing novel device-based therapies to treat patients with neurodegenerative disease. The company's first products will aim to halt the progression of ALS and PSP.

    ​At EnClear Therapies, leading scientific, and clinical minds in the field of neurodegenerative disease have come together with experts in medical device design to bring new therapies to patients who currently have no other options for treatment.​

    How much is an extra decade of life worth to you? Make a bet on longevity science today.

    Donate to Impetus Grants

    You May Also Be Interested In